Recent Updates
Recently added Catalysts
ABVX Positive Sentiment

Abivax Statement on Short Seller Report

Key Takeaway: Abivax issued a statement addressing inaccuracies in a report by Scorpion Capital. The company defends its clinical development program and plans to file an NDA with the FDA by the end of the year. Abivax highlights the report's misleading statements and the financial motives behind it.

Market Sentiment Analysis

POSITIVE FACTORS

  • Abivax defends its clinical development program.
  • The company plans to file an NDA with the FDA by year-end.
  • Abivax emphasizes the integrity of its clinical data.

CONCERNS & RISKS

  • The report from Scorpion Capital contains inaccuracies.
  • Scorpion Capital has a financial interest in Abivax's share price decline.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+29%
120-day peak, hindsight
Typical move
11%
average across 6 past catalysts
Lead asset
ABX464
Phase 3 · Ulcerative Colitis

Full Press Release Details

Abivax Statement on Short Seller Report

PARIS, France – November 20, 2026 – 10:30 PM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax,” the “Company,” “we” or “our”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today issued a statement regarding a report published by Scorpion Capital on November 20, 2026.
We are reviewing the Scorpion Capital report in detail and anticipate providing further updates regarding this matter. Based on Abivax’s current review, it is clear that the report contains numerous factually inaccurate and misleading statements, assumptions, and conclusions, including those based on studies commissioned and funded by Scorpion Capital itself. We firmly stand behind the integrity of our clinical development program, including the results of our Phase 3 ABTECT trials and the strength of the clinical data generated to date, which will support Abivax’s U.S. FDA NDA filing by the end of the year.
Notably, Scorpion Capital explicitly disclosed its short position in Abivax and its intention to begin covering a substantial portion of that position upon publication of its report, underscoring its direct financial interest in a decline in our share price. These direct financial incentives provide important context for evaluating the report.

About Abivax

Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.

Contact: Patrick Malloy SVP, Investor Relations Abivax SA patrick.malloy@abivax.com +1 847 987 4878

Media Contacts: LifeSci Communications Karissa Baltz, PhD Associate Director LSC_ABIVAX@lifescicomms.com

Longacre Square Partners Abivax@longacresquare.com

Frequently Asked Questions

What did Abivax say about the Scorpion Capital report?

Abivax stated the report contains numerous inaccuracies and misleading statements.

What is Abivax's lead drug candidate?

Abivax's lead drug candidate is obefazimod (ABX464).

When does Abivax plan to file its NDA with the FDA?

Abivax plans to file its NDA by the end of the year.

What is Scorpion Capital's interest in Abivax?

Scorpion Capital has a short position in Abivax, aiming to profit from a price decline.

Last updated: Nov 20, 2026